Metabolism of Prostaglandin F2α in Early Human Placenta  in vitro

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The authors were investigating the metabolism of prostaglandin F2α in human early placenta, in in vitro incubation experiments. They have identified both major metabolites, 15-keto-PGF2α and 15-keto-13, 14 dehydro PGF2α. They have examined the change in the percentage of these, taken as a function of time. They have established that the main site of inactivating the endogenous PGF2α is the early human placenta. They suppose that the considerable Pg-inactiviting effect of the placenta has a part which acts as a protecting mechanism in preventing the uterotonic influence of the endogenous prostaglandins.

Related collections

Author and article information

Journal

Journal ID (publisher-id): HRE

Journal ID (nlm-ta): Horm Res Paediatr

Journal ID (doi): 10.1159/issn.1663-2818

Title: Hormone Research in Paediatrics

Publisher: S. Karger AG

ISSN (Print): 1663-2818

ISSN (Electronic): 1663-2826

Publication date Subscription-year: 1977

Publication date (Print): 1977

Publication date (Electronic): 25 November 2008

Volume: 8

Issue: 2

Pages: 99-106

Affiliations

WHO Clinical Research Center on Human Reproduction, University Medical School of Szeged, Szeged

Article

Publisher ID: 178786 Other ID: Horm Res 1977;8:99–106

DOI: 10.1159/000178786

PubMed ID: 908555

SO-VID: 111f00bb-48bd-4cce-8125-76b7c37cf350

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Metabolism of Prostaglandin F2α in Early Human Placenta in vitro

Read this article at

Abstract

Related collections

Karger: Endocrinology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 519